Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.32
- Piotroski Score 5.00
- Grade Buy
- Symbol (GOSS)
- Company Gossamer Bio, Inc.
- Price $0.98
- Changes Percentage (2.47%)
- Change $0.02
- Day Low $0.97
- Day High $1.00
- Year High $1.60
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $4.00
- High Stock Price Target $5.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.85
- Trailing P/E Ratio -0.65
- Forward P/E Ratio -0.65
- P/E Growth -0.65
- Net Income $-179,817,000
Income Statement
Quarterly
Annual
Latest News of GOSS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Jon Gosselin Says Son Collin Is 'Moving Forward' at Penn State amid Estrangement from Mom Kate
Jon Gosselin's son, Collin, has moved on from his time in the Marines and is now a freshman at Penn State. Collin recently spoke out about alleged abuse by his mother, Kate, detailing a disturbing acc...
By PEOPLE.com | 3 days ago -
Sebastian Stan Hints Gossip Girl Costar Leighton Meester Was His First 'Serious Love': 'Life Seemed Simpler'
Actor Adam Brody reflected on his first serious relationship during his time on Gossip Girl, praising ex Leighton Meester's talent and humor. Meester also shared insights on relationships, emphasizing...
By PEOPLE.com | 1 week ago -
Mark-Paul Gosselaar Flips the Script and Takes Control in Found Season 2: See the Chilling Trailer (Exclusive)
The new season of "Found" follows Gabi Mosely as her worst nightmare becomes reality when a man from her past resurfaces. As she races to save her sister, she must confront her chilling past and make ...
By PEOPLE.com | 1 week ago